Brainomix used its AI imaging platform, Brainomix 360 Stroke, to analyze data from a Phase II clinical study of ARG-007, a novel neuroprotective drug candidate in severe acute ischemic stroke patients. The AI-enabled assessment standardized baseline stroke severity and quantified treatment responses, revealing statistically significant changes in imaging biomarkers and clinical measures in patients with larger brain infarcts.
